Neurocrine Biosciences heads into tonight's Q2 earnings report with analysts raising targets, the stock near a multi-month high, and short sellers in retreat — a setup where the bull case is already partly priced in.
The analyst community has shifted decisively more constructive in the weeks before the print. Multiple firms raised price targets in July, with Guggenheim and Wells Fargo both moving to $200 from $175, and Truist lifting its target all the way from $155 to $200. RBC Capital went to $195. Goldman Sachs reinstated coverage in early June at $213, and Bernstein set a $221 target at initiation in May. The consensus now sits at a Buy with a mean target of $202 — roughly 9% above Thursday's close of $185.50. BMO Capital, the lone more cautious voice, raised to $170 while keeping a Market Perform. The direction of travel is clear: the Street is broadly bullish, but targets are clustered in the $195–$221 range, leaving limited room for further re-rating unless the print surprises materially.
The bull case centres on Crenessity's commercial momentum and improving insurance coverage dynamics, alongside Ingrezza's continued growth and a pipeline with catalysts expected in 2027–2028. Bears acknowledge the commercial execution but point to competitive risk in the movement disorder franchise, pricing pressure, and the still-early-stage nature of higher-upside pipeline assets like the Friedreich's Ataxia gene therapy. Valuation is no longer cheap: the P/E stands around 15.7x and EV/EBITDA near 13x, with both multiples drifting lower over the past 30 days as the stock has climbed roughly 9% on the month — a sign the market is already demanding delivery.
Short sellers have been moving the other way. Short interest has fallen nearly 9% over the past week to 5.2% of the free float — still a meaningful position, but the trend is clearly toward covering ahead of the print. Borrowing costs are negligible at 0.37% and availability is extremely loose at nearly 3,000% — meaning there is no scarcity of shares to borrow and no squeeze dynamic building. The ORTEX short score has eased from around 43 two weeks ago to 41, corroborating the reduction in bearish conviction. Options are slightly more defensive than usual: the put/call ratio has edged up to 0.88, about 1.6 standard deviations above its 20-day average, suggesting some incremental hedging activity even as the broader positioning skews bullish. Notably, NBIX rose more than 9% in the day following Q1 results in May and extended that move to 16% over five days — a reminder of how sharply the stock can re-rate when it delivers.
The Q2 print is ultimately a test of whether Crenessity's commercial ramp and Ingrezza's durability can justify an analyst community that has already moved its targets well above current levels, and whether the stock's 9% monthly gain has anticipated the good news or merely set the stage for it.
See the live data behind this article on ORTEX.
Open NBIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
